Edition:
United Kingdom

Profile: Catalent Inc (CTLT.N)

CTLT.N on New York Stock Exchange

46.41USD
5:57pm BST
Change (% chg)

$0.22 (+0.48%)
Prev Close
$46.19
Open
$46.36
Day's High
$46.96
Day's Low
$46.10
Volume
39,145
Avg. Vol
214,963
52-wk High
$47.03
52-wk Low
$29.26

Catalent, Inc., incorporated on March 14, 2007, is a provider of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The Company's segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels, including traditional softgel capsules (in which the shell is made from animal-derived materials), and Vegicaps and OptiShell capsules (in which the shell is made from vegetable-derived materials). The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products using its OptiMelt, OptiPact, OptiForm and Zydis technologies, other drug delivery technologies, such as prefilled syringes; blow-fill seal unit dose manufacturing, including its ADVASEPT technology; biologic cell line development, including its GPEx and SMARTag technologies; and analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for customer required patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Softgel Technologies

The Softgel Technologies segment provides formulation, development and manufacturing services for soft capsules or softgels. Softgel capsules are used in a range of customer products, including prescription drugs, over-the-counter medications, dietary supplements and unit-dose cosmetics. Softgel capsules encapsulate liquid, paste or oil-based active compounds in solution or suspension within an outer shell, filling and sealing the capsule simultaneously. The Company also participates in the softgel vitamin, mineral and supplement business in selected regions around the world.

Drug Delivery Solutions

The Drug Delivery Solutions segment provides various formulation delivery technologies, and related integrated solutions, including development and manufacturing of a range of oral dose forms, including fast-dissolve tablets and both proprietary and conventional controlled release products, and delivery of pharmaceuticals, biologics and biosimilars administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Company provides pre-formulation, development, and both clinical and commercial scale for traditional and advanced oral solid dose formats, including uncoated and coated tablets, powder/pellet/bead-filled two piece hard capsules, lozenges, powders and other forms for immediate and modified release prescription, consumer and animal health products.

The Company's range of injectable manufacturing offerings includes filling drugs or biologics into pre-filled syringes and glass-free ADVASEPT vials. Blow-fill-seal is an aseptic processing technology, which uses a continuous process to form, fill with drug, and seal a plastic container in a sterile environment. Blow-fill-seal units are used for a range of pharmaceuticals in liquid form, such as respiratory, ophthalmic and otic products. The business provides engineering and manufacturing solutions related to complex containers. The Company's biologics offerings include formulation development and cell-line manufacturing based on its GPEx technology, which is used to develop mammalian cell lines for both innovator and biosimilar biologic compounds.

The Company offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, micronization and particle engineering services, regulatory consulting, and bio analytical testing for biologic products. Its respiratory product features include development and manufacturing services for inhaled products for delivery through metered dose inhalers, dry powder inhalers and intra-nasal sprays. The Company also provides formulation development and clinical and commercial manufacturing for conventional and specialty oral dose forms.

Clinical Supply Services

The Clinical Supply Services segment offers solutions for clinical supplies production, and provides distribution and inventory management support for both simple and complex clinical trials. This includes dose form manufacturing or over-encapsulation where needed; supplying placebos, comparator drug procurement and clinical packages and kits for physicians and patients; inventory management; investigator kit ordering and fulfillment, and return supply reconciliation and reporting.

The Company competes with Biomet, Inc., Emcure Pharmaceuticals Ltd., Apria Healthcare Group Inc., Nycomed Holding A/S, DJO Global LLC, Independent Clinical Services Ltd, Southern Cross Healthcare Group PLC, Stiefel Laboratories, Inc., Team Health Holdings, Inc. and Vanguard Health Systems, Inc.

Company Address

Catalent Inc

14 Schoolhouse Rd
SOMERSET   NJ   08873-1213
P: +1732.5376200
F: +1732.5376480

Company Web Links